One-paragraph summary (for email, talk, or present
Post# of 157825
(Total Views: 525)
Posted On: 05/01/2025 5:11:11 PM
One-paragraph summary (for email, talk, or presentation)
Metastatic triple-negative breast cancer (mTNBC) is one of the most aggressive and difficult-to-treat breast cancers, with median overall survival (mOS) dropping from ~12–17 months in first-line treatment to ~6–7 months in late-line settings. While drugs like Trodelvy have extended survival in late-line mTNBC to around 12 months, investigational therapies like leronlimab are showing remarkable promise. In a small trial, leronlimab achieved long-term survival beyond 36 months in a subset of patients — an unprecedented outcome in this population. If these results are confirmed in larger studies, leronlimab could represent a paradigm shift for late-line mTNBC, offering new hope where few options exist.
Brief explanation: How CCR5 blockade (leronlimab) works in cancer
CCR5 is a receptor found on immune cells and some cancer cells, and it plays a role in immune regulation, inflammation, and cancer spread (metastasis). Many aggressive cancers, including mTNBC, exploit CCR5 to escape immune detection and promote metastasis. Leronlimab blocks CCR5, potentially stopping tumor cells from migrating, reducing immune suppression, and improving the body’s ability to attack the cancer. This mechanism is different from chemotherapy or antibody-drug conjugates, making it a unique and promising addition to the mTNBC treatment arsenal.
Metastatic triple-negative breast cancer (mTNBC) is one of the most aggressive and difficult-to-treat breast cancers, with median overall survival (mOS) dropping from ~12–17 months in first-line treatment to ~6–7 months in late-line settings. While drugs like Trodelvy have extended survival in late-line mTNBC to around 12 months, investigational therapies like leronlimab are showing remarkable promise. In a small trial, leronlimab achieved long-term survival beyond 36 months in a subset of patients — an unprecedented outcome in this population. If these results are confirmed in larger studies, leronlimab could represent a paradigm shift for late-line mTNBC, offering new hope where few options exist.
Brief explanation: How CCR5 blockade (leronlimab) works in cancer
CCR5 is a receptor found on immune cells and some cancer cells, and it plays a role in immune regulation, inflammation, and cancer spread (metastasis). Many aggressive cancers, including mTNBC, exploit CCR5 to escape immune detection and promote metastasis. Leronlimab blocks CCR5, potentially stopping tumor cells from migrating, reducing immune suppression, and improving the body’s ability to attack the cancer. This mechanism is different from chemotherapy or antibody-drug conjugates, making it a unique and promising addition to the mTNBC treatment arsenal.
(8)
(0)